Receptor-bound uPA is reversibly protected from inhibition by low molecular weight inhibitors.
Urokinase-type plasminogen activator (uPA) plays a ubiquitous role in cell migration and invasiveness. Amiloride, a competitive inhibitor of uPA, can inhibit endothelial cell (EC) outgrowth during angiogenesis. To address the question of whether amiloride blocked angiogenesis by inhibiting uPA, we undertook a study of uPA expression in sprouting EC in vitro and the effects of amiloride on both enzymatic and morphogenetic activity. As expected, amiloride inhibited soluble uPA (suPA) with an IC(50) of 45-85 microm, however, receptor-bound uPA (rbuPA) from the sprouting EC was insensitive to amiloride. Removal of uPA from its receptors confers sensitivity to inhibition by amiloride suggesting that a reversible conformational change may mediate the insensitivity of rbuPA to amiloride and its analogs. In summary, we found no evidence to support the hypothesis that amiloride blocks capillary outgrowth by inhibition of uPA, but were able to successfully demonstrate a functional difference between two physiological forms of this important matrix-degrading enzyme.
Dyer
Kimberly D
KD
Laboratory of Host Defenses, NIAID, Bethesda, MD 20892-1886, USA. kdyer@niaid.nih.gov
Linz-Mcgillem
Laura A
LA
Alliegro
Mary Anne
MA
Alliegro
Mark C
MC
D000584:Amiloride / Q000378:metabolism* / Q000494:pharmacology; D000818:Animals; D004730:Endothelium, Vascular / Q000378:metabolism; D008264:Macrophages / Q000378:metabolism; D051379:Mice; D018919:Neovascularization, Physiologic / Q000187:drug effects*; D010958:Plasminogen / Q000378:metabolism; D013552:Swine; D014568:Urokinase-Type Plasminogen Activator / Q000037:antagonists & inhibitors* / Q000378:metabolism
D000584:Amiloride; D010958:Plasminogen; D014568:Urokinase-Type Plasminogen Activator